Investor News
Annual Report & Accounts 2018 and Annual General Meeting 2019
INDIVIOR PLC (THE ‘COMPANY’) ANNUAL REPORT AND ACCOUNTS FOR THE YEAR-ENDED DECEMBER 31, 2018 (‘ANNUAL…
Read moreThe Journal of Addiction Medicine Publishes Patient-centered Outcomes from the Phase 3 Study of SUBLOCADE™ (Buprenorphine Extended-Release) Injection in Patients with Moderate to Severe Opioid Use Disorder (OUD)
Read moreIndivior Announces Launch of PERSERIS™ (risperidone) for the Treatment of Schizophrenia in Adults
Read moreIndivior Announces Launch of SUBOXONE® (buprenorphine and naloxone) Sublingual Film Authorized Generic
Read moreThe Lancet Publishes Phase 3 Results Demonstrating Efficacy, Safety and Tolerability of SUBLOCADE™ (Buprenorphine Extended-Release) Injection for Subcutaneous Use (CIII) in Patients with Moderate to Severe Opioid Use Disorder (OUD)
Read moreFY 2018 Results Presentation Webcast
Read morePresentation: Indivior FY 2018 Results Presentation (February 14)
PDF Presentation can be downloaded here
Read moreIndivior PLC FY 2018 Financial Results
Read moreFY 2018 Results Presentation on February 14ᵗʰ
11:30 GMT / 6:30 a.m. U.S. Eastern Link here: https://edge.media-server.com/m6/p/at8xatmw
Read more